Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer?

Area of Science:

• Oncology
• Cancer Biology
• Molecular Medicine

Background:

• Vascular Endothelial Growth Factor (VEGF) signaling is crucial for tumor angiogenesis and progression.
• Anti-VEGF therapies are widely used in cancer treatment but can lead to resistance.
• The role of c-Met signaling in mediating resistance to anti-VEGF therapy requires further elucidation.

Purpose of the Study:

• To investigate the mechanisms by which selective VEGF inhibition impacts tumor invasion and metastasis.
• To determine the role of c-Met signaling in mediating the effects of anti-VEGF therapy.
• To explore c-Met inhibition as a strategy to overcome anti-VEGF therapy-induced invasion.

Main Methods:

• Utilized the RIP-Tag2 mouse model of neuroendocrine pancreatic cancer.
• Administered selective anti-VEGF antibody therapy.
• Assessed tumor hypoxia, hypoxia-inducible factor 1α (HIF-1α) expression, and c-Met activation.
• Investigated the effects of selective c-Met inhibition.

Main Results:

• Selective VEGF inhibition significantly increased tumor invasion and metastasis.
• Anti-VEGF therapy led to increased tumor hypoxia, HIF-1α, and c-Met activation.
• Selective c-Met inhibition effectively blocked the pro-invasive effects induced by anti-VEGF therapy.

Conclusions:

• Selective VEGF inhibition promotes tumor invasion and metastasis in a c-Met-dependent manner.
• The combination of anti-VEGF and anti-c-Met therapies may represent a viable strategy to enhance treatment efficacy.
• Targeting c-Met offers a potential solution to overcome resistance mechanisms associated with anti-VEGF therapy.